Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma.

HLA-A*02 allele expression might not only predict better survival but might also indicate superior tumor antigen presentation and, thus, help to select patients who could benefit from T-cell-dependent immunotherapies.